ClinicalTrials.gg
SuspendedNCT05291390PILUpdated Oct 19, 2026

Pyronaridine in Acute Myeloid Leukemia (AML)

A Phase 2 interventional study of Pyronaridine Tetraphosphate in Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL), sponsored by Armaceutica, Inc.. Suspended at 1 site in Senegal. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Armaceutica, Inc. · Phase 2, Interventional, and Treatment

Why this study was suspended
Change of protocol
Updated Oct 19, 2026Now SuspendedStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase 2a clinical trial on up to n=200 male and female subjects 18 years and over who were diagnosed with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Subjects are randomised in approximately a 1:1 ratio to receive standard of care treatment plus either pyronaridine (PND) or placebo. Quality of life parameters are measured. Visits include physical examinations, and blood draws for complete blood count with differential (CBC) and complete metabolic panel (CMP). Survival of subjects is tracked in Year 2.

Read the detailed description

The primary objective is the difference in survival lengths in days between the study arm receiving pyronaridine and the study arm receiving placebo as measured from the date of the first diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Secondary objectives are differences between the active and placebo study arms in quality of life, laboratory data values and in the safety and tolerability of treatments.

02

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Acute Lymphoblastic Leukemia (ALL)

Keywords

  • cancer
  • leukemia
  • phase 2
  • pyronaridine
  • oncology
  • treatment
03

In context

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

This study's planned enrollment of 200 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

This is the only study on the registry with Armaceutica, Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must have a diagnosis within 60 days of the time of study entry of either acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). If the physician is a third-party physician, then the study site must obtain the subject's medical records from the clinic where the first diagnosis was made.
  2. Subjects must be on standard of care therapy for ALL or AML. The standard of care therapy may be initiated at time of study entry.
  3. Subjects must be 18 years of age or older, and male or female.
  4. Subjects must weigh between 40kg and 90kg at time of study entry.
  5. Women of must agree to use adequate (hormonal or barrier method of birth control or abstinence) at least 14 days prior to study entry, for the duration of study participation, and at least 30 days after completion of drug administration. Women of child-bearing potential must agree to pregnancy tests for the duration of the study. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the study subject should inform her investigator immediately.
  6. Men must agree to always use a condom during intercourse for the duration of study participation, and for at least 30 days after completion of drug administration.
  7. Subjects must have the ability to swallow size "0" gelatin capsules.
  8. Subject must be willing to agree to and comply with all requirements of the study.
  9. Subjects must have the ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with malaria.
  2. Subjects who are pregnant or nursing.
  3. Subjects who have had major surgery within 30 days prior to study entry.
  4. Subjects with active infection or uncontrolled illness, except ALL or AML.
  5. Subjects with evidence of chronic (HBV) infection.
  6. Subjects with evidence or history of (HCV) infection.
  7. Subjects with a prior or concurrent (basal cell carcinoma and squamous cell skin cancer are allowed).
  8. Subjects with evidence of other disease or any concomitant medical or psychiatric problem which in the opinion of the investigator would put them at risk.
  9. Subjects with a known to pyronaridine tetraphosphate or compounds of similar chemical composition, or microcrystalline cellulose (MCC) the placebo agent.
  10. Subjects who are receiving any other agents or who have received any investigational medication within the past 30 days.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Standard of care treatment plus pyronaridine

    Standard of care treatment plus pyronaridine

    Drug: Pyronaridine Tetraphosphate

  • Placebo comparator
    Standard of care treatment plus placebo

    Standard of care treatment plus placebo

    Drug: Pyronaridine Tetraphosphate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in survival lengths to 1 year

    The primary endpoint is the change in survival lengths in days between the study arm receiving pyronaridine and the study arm receiving placebo as measured from the date of the first known acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) diagnosis within 60 days of the time of study entry.

    Time frame: 1 year

07

Study locations

1 site
  • Dalal Jamm Hospital
    Guediawaye GOL SUD, Dakar B P 19 001, Senegal
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Feb 2028; primary completion for Feb 2030, 24 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Nov 2022 → Feb 2028, primary completion Feb 2024 → Feb 2030 and completion Mar 2024 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2021
First posted
Mar 22, 2022
StartEst.
Feb 21, 2028was Nov 2022
Primary completionEst.
Feb 2030was Feb 2024
CompletionEst.
Mar 2030was Mar 2024
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Suspended Change of protocol
changed Oct 19, 2026
Start date
Nov 21, 2022→Feb 21, 2028
Oct 19, 2026
Primary completion
Feb 2024→Feb 2030
Oct 19, 2026
Study completion
Mar 2024→Mar 2030
Oct 19, 2026
Title
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Oct 19, 2026
Sponsor
Collaborators removed: Uganda Cancer Institute
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Status unknown→Suspended
    Why stopped Change of protocol
    Start date Nov 21, 2022→Feb 21, 2028
    Primary completion Feb 2024→Feb 2030
    Study completion Mar 2024→Mar 2030
    Sponsor Collaborators removed: Uganda Cancer Institute
    Title Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05291390
Lead sponsor
Armaceutica, Inc.
Collaborators
African Center for Cancer Research and End of Life Care (ACREOL), Rwanda, Ifakara Health Research and Development Centre, Dalal Jamm Hospital, Dakar, Senegal
Responsible party
Sponsor
First posted
Mar 22, 2022
Start date
Feb 21, 2028 (estimated)
Primary completion
Feb 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Renato J Aguilera, PhD
study chair · Armaceutica, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyronaridine

Start the discussion